ArticleFrontiers in endocrinology2023
Development and validation of a diabetic retinopathy risk prediction model for middle-aged patients with type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Risk prediction models for diabetic retinopathy: a systematic review.Frontiers in endocrinology · 2025Pooled it
- Association of Hyperuricemia with the Onset and Progression of Type 2 Diabetic Retinopathy.Journal of clinical medicine · 2026Article
- A Novel Nomogram for Diabetic Retinopathy Prediction in Young and Middle-Aged Patients with Type 2 Diabetes.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Development and comparison of OCT-based prediction models for diabetic retinopathy using LASSO and random forest.Medicine · 2025Article
- Development of machine learning predictive model for type 2 diabetic retinopathy using the triglyceride-glucose index explained by SHAP method.Frontiers in endocrinology · 2025Article
- Red blood cell count and its inverse association with diabetic retinopathy: Exploratory development of a risk assessment model in a retrospective cohort.Frontiers in endocrinology · 2025Article
- Screening and evaluation of diabetic retinopathyWorld journal of diabetes · 2024Article
- Review
- Development and external validation of a predictive model for type 2 diabetic retinopathy.Scientific reports · 2024Article
- Development and validation of a cognitive dysfunction risk prediction model for the abdominal obesity population.Frontiers in endocrinology · 2024Article
- Predictive model and risk analysis for peripheral vascular disease in type 2 diabetes mellitus patients using machine learning and shapley additive explanation.Frontiers in endocrinology · 2024Article
- Association between Serum Phosphorus Levels and Diabetic Retinopathy: A Cross-Sectional Study.International journal of endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The study aims to establish a predictive nomogram of diabetic retinopathy(DR) for the middle-aged population with type 2 diabetes mellitus (T2DM). Methods: This retrospective study screened 931 patients with T2DM between 30 and 59 years of age from the 2011-2018 National Health and Nutrition Examination Survey database. The development group comprised 704 participants from the 2011-2016 survey, and the validation group included 227 participants from the 2017-2018 survey. The least absolute shrinkage and selection operator regression model was used to determine the best predictive variables. The logistic regression analysis built three models: the full model, the multiple fractional polynomial (MFP) model, and the stepwise (stepAIC) selected model. Then we decided optimal model based on the receiver operating characteristic curve (ROC). ROC, calibration curve, Hosmer-Lemeshow test, and decision curve analysis (DCA) were used to validate and assess the model. An online dynamic nomogram prediction tool was also constructed. Results: The MFP model was selected to be the final model, including gender, the use of insulin, duration of diabetes, urinary albumin-to-creatinine ratio, and serum phosphorus. The AUC was 0.709 in the development set and 0.704 in the validation set. According to the ROC, calibration curves, and Hosmer-Lemeshow test, the nomogram demonstrated good coherence. The nomogram was clinically helpful, according to DCA. Conclusion: This study established and validated a predictive model for DR in the mid-life T2DM population, which can assist clinicians quickly determining who is prone to develop DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.